



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO	FILED DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09.065.902	04.24.1998	RUDOLPH E. TANZI	0609.4270001	8113

7590 01.02.2002

STERNE KESSLER GOLDSTEIN & FOX
1100 NEW YORK AVENUE NW
SUITE 600
WASHINGTON, DC 200053934

EXAMINER

NOLAN, PATRICK J

ART UNIT	PAPER NUMBER
1644	

DATE MAILED: 01.02.2002 25

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/065,902	Applicant(s) Tanzi et al.	Examiner Patrick J. Nolan	Art Unit 1644	
-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE <u>3</u> MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.					
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.					
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.					
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.					
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).					
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status					
1) <input checked="" type="checkbox"/> Responsive to communication(s) filed on <u>Oct 22, 2001</u>					
2a) <input type="checkbox"/> This action is FINAL . 2b) <input checked="" type="checkbox"/> This action is non-final.					
3) <input type="checkbox"/> Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposition of Claims					
4) <input checked="" type="checkbox"/> Claim(s) <u>2-5, 9, and 10</u> is/are pending in the application.					
4a) Of the above, claim(s) _____ is/are withdrawn from consideration.					
5) <input type="checkbox"/> Claim(s) _____ is/are allowed.					
6) <input checked="" type="checkbox"/> Claim(s) <u>2-5, 9, and 10</u> is/are rejected.					
7) <input type="checkbox"/> Claim(s) _____ is/are objected to.					
8) <input type="checkbox"/> Claims _____ are subject to restriction and/or election requirement.					
Application Papers					
9) <input type="checkbox"/> The specification is objected to by the Examiner.					
10) <input type="checkbox"/> The drawing(s) filed on _____ is/are objected to by the Examiner.					
11) <input type="checkbox"/> The proposed drawing correction filed on _____ is: a) <input type="checkbox"/> approved b) <input type="checkbox"/> disapproved.					
12) <input type="checkbox"/> The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. § 119					
13) <input type="checkbox"/> Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).					
a) <input type="checkbox"/> All b) <input type="checkbox"/> Some* c) <input type="checkbox"/> None of:					
1. <input type="checkbox"/> Certified copies of the priority documents have been received.					
2. <input type="checkbox"/> Certified copies of the priority documents have been received in Application No. _____.					
3. <input type="checkbox"/> Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
*See the attached detailed Office action for a list of the certified copies not received.					
14) <input type="checkbox"/> Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
Attachment(s)					
15) <input type="checkbox"/> Notice of References Cited (PTO-892)			18) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____		
16) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)			19) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)		
17) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____			20) <input type="checkbox"/> Other: _____		

Part III DETAILED ACTION

1. Claims 2-5 and 9-10 are pending.

2. The request filed on 10-22-01 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/065,902 is acceptable and a CPA has been established. An action on the CPA follows.

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 2-5 and 9-10 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is insufficient written description to show that Applicant was in possession of an antibody which binds to any "purified 20kDa presenilin-2 C-terminal fragment". The term "20kDa presenilin-2 C-terminal fragment" would include an essentially unlimited number of undefined compounds. One of skill in the art would therefore conclude that the specification fails to disclose a representative number of species to describe the claimed genus. See *Eli Lilly*, 119 F.3d 1559, 43 USPQ2d 1398. In addition Applicant is directed to the guidelines published in the Federal Register Vol. 66, No. 4, Friday January 5, 2001

For each claim drawn to a genus:

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is

substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. On the other hand, there may be situations where one species adequately supports a genus. What constitutes a "representative number" is an inverse function of the skill and knowledge in the art. Satisfactory disclosure of a "representative number" depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features of the elements possessed by the members of the genus in view of the species disclosed. For inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus. Description of a representative number of species does not require the description to be of such specificity that it would provide individual support for each species that the genus embraces. If a representative number of adequately described species are not disclosed for a genus, the claim to that genus must be rejected as lacking adequate written description under 35 USC 112 1st paragraph.

5. Applicant is requested to supply a copy of Kim et al., Journal of Neurobiology of Aging, Volume 17, 1996, S155, as cited in Tanzi et al., Alzheimer's Dis. Rev. 1:90-98, 1996. Since this publication is Applicant's own work the Examiner believes no undue burden has been placed on Applicant to supply said article in a PTO-1449.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Patrick Nolan whose telephone number is (703) 305-1987. The examiner can normally be reached on Tuesday through Friday from 9:30 am to 4:30 pm.

7. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Christina Chan, can be reached at (703) 305-3973. The FAX number for our group, 1644, is (703) 305-7939. Any inquiry of a general nature relating to the status of this application or proceeding should be directed to the Group receptionist, whose telephone number is (703) 308-0196.

Patent J. Nolan
Patrick J. Nolan, Ph.D.
Primary Examiner, Group 1640
December 29, 2001